Truist Financial Corp Sells 27,425 Shares of Catalent, Inc. (NYSE:CTLT)

Truist Financial Corp cut its stake in Catalent, Inc. (NYSE:CTLT) by 32.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 55,915 shares of the company’s stock after selling 27,425 shares during the period. Truist Financial Corp’s holdings in Catalent were worth $2,512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after buying an additional 365,648 shares during the period. Cadian Capital Management LP lifted its position in shares of Catalent by 91.0% in the 3rd quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock worth $241,527,000 after acquiring an additional 2,526,750 shares during the period. Barclays PLC grew its holdings in shares of Catalent by 41.7% during the 3rd quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock worth $218,440,000 after purchasing an additional 1,412,058 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Catalent by 65.9% during the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Catalent by 13.6% in the third quarter. Northern Trust Corp now owns 2,160,603 shares of the company’s stock valued at $98,372,000 after purchasing an additional 258,482 shares in the last quarter.

Catalent Stock Down 0.6 %

NYSE CTLT opened at $56.18 on Thursday. The stock’s 50 day simple moving average is $56.37 and its 200 day simple moving average is $49.31. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20. The firm has a market cap of $10.17 billion, a PE ratio of -8.26, a price-to-earnings-growth ratio of 6.09 and a beta of 1.18. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the company posted $0.62 EPS. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. As a group, sell-side analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on CTLT. StockNews.com started coverage on shares of Catalent in a research note on Sunday. They set a “sell” rating on the stock. Barclays lifted their target price on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. UBS Group reissued a “neutral” rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Stephens restated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.